125 related articles for article (PubMed ID: 38218180)
21. Role of CD93 in Health and Disease.
Tossetta G; Piani F; Borghi C; Marzioni D
Cells; 2023 Jul; 12(13):. PubMed ID: 37443812
[TBL] [Abstract][Full Text] [Related]
22. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment.
Li Z; Zhang XJ; Sun CY; Fei H; Li ZF; Zhao DB
World J Clin Cases; 2023 Feb; 11(4):738-755. PubMed ID: 36818626
[TBL] [Abstract][Full Text] [Related]
23. The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.
Tosi GM; Neri G; Barbera S; Mundo L; Parolini B; Lazzi S; Lugano R; Poletto E; Leoncini L; Pertile G; Mongiat M; Dimberg A; Galvagni F; Orlandini M
Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):30. PubMed ID: 32697305
[TBL] [Abstract][Full Text] [Related]
24. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound Imaging of Tumor Vascular CD93 with MMRN2 Modified Microbubbles for Immune Microenvironment Prediction.
Wang D; Xing C; Liang Y; Wang C; Zhao P; Liang X; Li Q; Yuan L
Adv Mater; 2024 May; 36(18):e2310421. PubMed ID: 38270289
[TBL] [Abstract][Full Text] [Related]
26. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
27. CD93 interacts with the PDZ domain-containing adaptor protein GIPC: implications in the modulation of phagocytosis.
Bohlson SS; Zhang M; Ortiz CE; Tenner AJ
J Leukoc Biol; 2005 Jan; 77(1):80-9. PubMed ID: 15459234
[TBL] [Abstract][Full Text] [Related]
28. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling.
Pen A; Moreno MJ; Durocher Y; Deb-Rinker P; Stanimirovic DB
Oncogene; 2008 Nov; 27(54):6834-44. PubMed ID: 18711401
[TBL] [Abstract][Full Text] [Related]
29. Regulation of CD93 cell surface expression by protein kinase C isoenzymes.
Ikewaki N; Kulski JK; Inoko H
Microbiol Immunol; 2006; 50(2):93-103. PubMed ID: 16490927
[TBL] [Abstract][Full Text] [Related]
30. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma.
Bohlson SS; Silva R; Fonseca MI; Tenner AJ
J Immunol; 2005 Jul; 175(2):1239-47. PubMed ID: 16002728
[TBL] [Abstract][Full Text] [Related]
31. CD93 Blockade Stabilizes Tumor Vasculature to Improve Therapy Response.
Cancer Discov; 2021 Oct; 11(10):2368. PubMed ID: 34362767
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
[TBL] [Abstract][Full Text] [Related]
33. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
34. CD93 a potential player in cytotrophoblast and endothelial cell migration.
Fantone S; Tossetta G; Di Simone N; Tersigni C; Scambia G; Marcheggiani F; Giannubilo SR; Marzioni D
Cell Tissue Res; 2022 Jan; 387(1):123-130. PubMed ID: 34674045
[TBL] [Abstract][Full Text] [Related]
35. CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells.
Barbera S; Raucci L; Lugano R; Tosi GM; Dimberg A; Santucci A; Galvagni F; Orlandini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830297
[TBL] [Abstract][Full Text] [Related]
36. CD93 maintains endothelial barrier function by limiting the phosphorylation and turnover of VE-cadherin.
Lugano R; Vemuri K; Barbera S; Orlandini M; Dejana E; Claesson-Welsh L; Dimberg A
FASEB J; 2023 Apr; 37(4):e22894. PubMed ID: 36961390
[TBL] [Abstract][Full Text] [Related]
37. Soluble expression of disulfide-bonded C-type lectin like domain of human CD93 in the cytoplasm of Escherichia coli.
Nativel B; Figuester A; Andries J; Planesse C; Couprie J; Gasque P; Viranaicken W; Iwema T
J Immunol Methods; 2016 Dec; 439():67-73. PubMed ID: 27742562
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines.
Pen A; Durocher Y; Slinn J; Rukhlova M; Charlebois C; Stanimirovic DB; Moreno MJ
Cancer Biol Ther; 2011 Oct; 12(7):634-46. PubMed ID: 21795858
[TBL] [Abstract][Full Text] [Related]
39. Association of insulin-like growth factor binding protein-7 promoter methylation with esophageal cancer in peripheral blood.
Kaya Z; Almalı N; Sahin ES; Duran S; Görgisen G; Ates C
Mol Biol Rep; 2022 May; 49(5):3423-3431. PubMed ID: 35076852
[TBL] [Abstract][Full Text] [Related]
40. CD93 and related family members: their role in innate immunity.
Greenlee MC; Sullivan SA; Bohlson SS
Curr Drug Targets; 2008 Feb; 9(2):130-8. PubMed ID: 18288964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
